Notice of Allowability	Application No.	Applicant(s)
	09/813,290	WALKE ET AL.
	Examiner	Art Unit
	B. Dell Chism	1654
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>Applicants' paper filed 26 March 2004</u> .		
2. The allowed claim(s) is/are 1-4,11 and 12.		
3. The drawings filed on are accepted by the Examiner.		
<ul> <li>4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some* c) None of the:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* Certified copies not received:</li> </ul>		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
<ul> <li>6. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.</li> <li>(a) including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached</li> <li>1) hereto or 2) to Paper No./Mail Date</li> <li>(b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date</li> <li>Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).</li> </ul>		
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)  1. ☐ Notice of References Cited (PTO-892)  2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)  3. ☑ Information Disclosure Statements (PTO-1449 or PTO/SB/0	6.	te
Paper No./Mail Date <u>27 Septem 2001</u> 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. 🏿 Examiner's Statem 9. ☐ Other	ent of Reasons for Allowance
Resident		

Application/Control Number: 09/813,290

Art Unit: 1654

## **DETAILED ACTION**

## **EXAMINER'S AMENDMENT**

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Peter Seferian on 09 June 2004.

The application has been amended as follows:

Claim 2, line 4, the phrase "or the complement thereof" is deleted.

Claim 2, line 3, the word --complement-- is inserted between the words "the" and "nucleotide".

2. The following is an examiner's statement of reasons for allowance:

The present application was rejected for a lack of utility under 35 U.S.C. § 101 and for lacking enablement under 35 U.S.C. § 112, first paragraph. This rejection is obviated by applicants' argument that the *asserted utility* of the present application is incorporated by reference to "[F]or example, U.S. Patents Nos. 5,981,222 and 5,935,865" both of which describe other semaphorins as well as applications and utilities. The applicants demonstrated that the presently claimed sequence contains the recognized semaphorin signaling domain present in human semaphorin sem2 and the sema domains which are know to those of skill in the art to occur in semaphorins, thus asserting function and structure. The nexus between the referenced US patents and the presently claimed sequences is the domains known by those of ordinary skill

Application/Control Number: 09/813,290

Art Unit: 1654

in the art as semaphorin functional domains, thus, the presently claimed sequences are allowed those utilities incorporated by reference in the above referenced US patents and are enabled for those products of those asserted utilities.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to B. Dell Chism whose telephone number is 571-272-0962. The examiner can normally be reached on 7:30 AM - 4:30 PM, Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on 571-272-0961. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306 for regular communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

B. Dell Chism

10 June 2004

CHRISTOPHER R. TATE PRIMARY EXAMINER